A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

Multicenter Phase ◽

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-15-2225 ◽

2016 ◽

Vol 22 (12) ◽

pp. 2874-2884 ◽

Cited By ~ 55

Author(s):

Saoirse O. Dolly ◽

Andrew J. Wagner ◽

Johanna C. Bendell ◽

Hedy L. Kindler ◽

Lee M. Krug ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Advanced Solid Tumors ◽

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Annals of Oncology ◽

10.1093/annonc/mdw282 ◽

2016 ◽

Vol 27 (10) ◽

pp. 1928-1940 ◽

Cited By ~ 100

Author(s):

A. Patnaik ◽

L.J. Appleman ◽

A.W. Tolcher ◽

K.P. Papadopoulos ◽

M. Beeram ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Kinase Inhibitor ◽

Class I ◽

Advanced Solid Tumors ◽

Hodgkin's Lymphomas ◽

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3‐Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations

The Oncologist ◽

10.1634/theoncologist.2019-0297 ◽

2019 ◽

Vol 25 (1) ◽

Cited By ~ 10

Author(s):

Aditya Bardia ◽

Mrinal Gounder ◽

Jordi Rodon ◽

Filip Janku ◽

Martijn P. Lolkema ◽

...

Keyword(s):

Combination Therapy ◽

Solid Tumors ◽

Kinase Inhibitor ◽

Mek Inhibitor ◽

Advanced Solid Tumors ◽

Phase Ib ◽

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors

Investigational New Drugs ◽

10.1007/s10637-015-0300-0 ◽

2015 ◽

Vol 34 (1) ◽

pp. 66-74 ◽

Cited By ~ 8

Author(s):

Hiroshi Nokihara ◽

Yasuhide Yamada ◽

Yutaka Fujiwara ◽

Noboru Yamamoto ◽

Hiroshi Wakui ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

Kinase Inhibitor ◽

Japanese Patients ◽

Advanced Solid Tumors

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-14-0947 ◽

2014 ◽

Vol 21 (1) ◽

pp. 77-86 ◽

Cited By ~ 157

Author(s):

Debashis Sarker ◽

Joo Ern Ang ◽

Richard Baird ◽

Rebecca Kristeleit ◽

Krunal Shah ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Pi3k Inhibitor ◽

Class I ◽

Advanced Solid Tumors ◽

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mds011 ◽

2012 ◽

Vol 23 (9) ◽

pp. 2399-2408 ◽

Cited By ~ 96

Author(s):

B. Markman ◽

J. Tabernero ◽

I. Krop ◽

G.I. Shapiro ◽

L. Siu ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Mtor Inhibitor ◽

Advanced Solid Tumors ◽

Pharmacodynamic Study ◽

526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(14)70652-5 ◽

2014 ◽

Vol 50 ◽

pp. 171

Author(s):

Z. Wainberg ◽

J. Tabernero ◽

M.A. Maqueda ◽

S. Leong ◽

G. Del Conte ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Advanced Solid Tumors ◽

Faculty Opinions recommendation of Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718514016.793503134 ◽

2015 ◽

Author(s):

Qing Zhong

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

Advanced Solid Tumors

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

Investigational New Drugs ◽

10.1007/s10637-012-9865-z ◽

2012 ◽

Vol 31 (3) ◽

pp. 696-706 ◽

Cited By ~ 48

Author(s):

Don G. Morris ◽

Xiaolan Feng ◽

Lisa M. DiFrancesco ◽

Kevin Fonseca ◽

Peter A Forsyth ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

Advanced Solid Tumors ◽

Reovirus Type ◽

Intralesional Administration ◽

Type 3

Abstract CT115: Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors

10.1158/1538-7445.am2021-ct115 ◽

2021 ◽

Author(s):

Geraldine O'Sullivan Coyne ◽

Khanh T. Do ◽

Shivaani Kummar ◽

Naoko Takebe ◽

Sarina Piha-Paul ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Trial ◽

Advanced Solid Tumors